Finally, an UP-tick for a month end. Notwithstanding a 15% hit in Merck today (because one of their big-selling beta-blocker drug Zocor perhaps doesn’t work as advertised), the portfolio came in at -24.8% (since inception Mar07) vs -25.9% last month. That’s +1.1%. Drinks on me!
Not only that, REAP beat the S&P500 by 6.5% in the quarter. [...]
